TL;DR FOLFIRINOX chemotherapy extends median overall survival to 11 months in metastatic pancreatic cancer, compared to 8.5 months with gemcitabine plus nab-paclitaxel-based regimens [1] Only 49.1% of stage IV pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and treatment facility type [2] Dr.Bh arat Patodiya's multidisciplinary approach integrates medical oncology, surgical consultation, and personalized treat